Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) Stock Has Average Target Price of $38.33

Shares of Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX) have been given a consensus recommendation of “Buy” by the six ratings firms that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have given a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $38.33.

Several analysts have commented on the company. Leerink Partners set a $32.00 price target on Eloxx Pharmaceuticals and gave the company an “outperform” rating in a report on Friday, September 18th. Lucid Cap Mkts upgraded shares of Eloxx Pharmaceuticals to a “strong-buy” rating in a report on Thursday, August 20th. Weiss Ratings initiated coverage on shares of Eloxx Pharmaceuticals in a research report on Friday, August 14th. They issued a “sell (d)” rating on the stock. Lifesci Capital started coverage on shares of Eloxx Pharmaceuticals in a research report on Wednesday, July 22nd. They issued an “outperform” rating and a $40.00 target price on the stock. Finally, Wall Street Zen upgraded shares of Eloxx Pharmaceuticals to a “hold” rating in a report on Saturday, August 1st.

Eloxx Pharmaceuticals Stock Down 4.9%

Shares of NASDAQ:ELOX opened at $13.03 on Tuesday. The company has a market cap of $52.64 million, a P/E ratio of -8.46 and a beta of -1,960.42. Eloxx Pharmaceuticals has a 52 week low of $8.20 and a 52 week high of $23.40. The business has a fifty day simple moving average of $16.32 and a 200-day simple moving average of $15.11.

Eloxx Pharmaceuticals (NASDAQ:ELOX) last released its earnings results on Tuesday, August 11th. The company reported ($0.66) EPS for the quarter. Sell-side analysts expect that Eloxx Pharmaceuticals will post -2.61 earnings per share for the current fiscal year.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc was a clinical-stage biopharmaceutical company focused on developing treatments for rare genetic diseases caused by nonsense mutations. These mutations can cause cells to stop producing functional proteins, potentially leading to serious inherited disorders.

The company’s lead program, ELX-02, was a synthetic aminoglycoside designed to promote ribosomal read-through of premature stop signals in messenger RNA. Eloxx evaluated ELX-02 in clinical development for genetic conditions including cystinosis and explored its potential in other diseases involving nonsense mutations.

Eloxx also developed ZKN-013, an oral small-molecule program intended to address nonsense-mutation disorders.